top of page

First clinical trial of a treatment for glioblastoma has extended the lives of four patients.

First clinical trial of a treatment for glioblastoma has extended the lives of four patients.



The new cancer vaccine is based on the same technology used in Covid-19 vaccines, but with some key differences. It works by reprogramming the tumor microenvironment (TME) using a sample of the tumor itself.

The vaccine helps the immune system “recognize” the malignant tumor, and provides it with an “instruction manual” for the complete copy of the tumor, revealing the mechanism for turning on or off each gene in the tumor.

This leads to the reprogramming of the immune system's defenses against cancer, and a more successful attack.

In the latest clinical trial, 4 patients with glioblastoma received two or four doses of the vaccine, which led to significant and rapid immune activation, as the researchers observed (a few hours after giving the doses) a significant increase in “pro-inflammatory proteins,” which stimulate cells. Deadly white blood.

This resulted in short-term side effects, such as nausea, low-grade fever, and chills, which gradually subsided over the next day or two.

In this regard, oncologist and vaccine research pioneer, Elias Sior, from the University of Florida, said: “This was very surprising given how quickly the immune attack occurred, and this is crucial to uncovering the after-effects of the immune response.”


bottom of page